Despite steady demand for obesity medications, 49% of payers who do not currently cover GLP-1s for obesity would not do so at any price, a new
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Pharmalittle: We're reading about employer coverage of obesity drugs, another Sanofi setback, and more
ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
Drug spending is rising sharply, with high-cost GLP-1 medications driving nearly half of the incr | How RxSense helped a health…
The Trump administration has officially launched its new "bridge" model that brings GLP-1 coverage for weight loss to Medicare…
LAS VEGAS — As drug costs and spending continue to rise, the demand for solutions opens the door to closer collaboration between…
Healthcare costs continue to rise, making effective payer-provider collaboration more important than ever. Download this free…
Within 24 hours of injecting the first dose of a weight loss medication she received following a visit with a telehealth doctor,…
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward…
